IQVIA Holdings Inc. with ticker code (IQV) now have 19 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $312.00 and $235.00 suggesting an average analyst share price target price of $274.27. (at the time of writing). Given that the stocks previous close was at $233.65 this would indicate that there is a potential upside of 17.4%. The day 50 moving average is $222.80 while the 200 day moving average is $224.27. The market cap for the company is 43.25B. The stock price for the company is currently $237.26 USD
The potential market cap would be $50,771,935,566 based on the market consensus.
The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of 30.77, revenue per share of $83.16 and a 5.03% return on assets.
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.
